Dyne Therapeutics Inc. (DYN) NASDAQ
$23.86 0.21 (0.89%)
Market Cap: $2.06B
As of 04/19/24 04:00 PM EDT. Market closed.
Dyne Therapeutics Inc. (DYN)
NASDAQ
$23.86
0.21 (0.89%)
Market Cap: $2.06B
As of 04/19/24 04:00 PM EDT. Market closed.
Add to Portfolio
dyne therapeutics, inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the united states. it develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its ... read more
dyne therapeutics, inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the united states. it develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its force platform that delivers disease-modifying therapies. the company was founded in 2017 and is based in waltham, massachusetts. read less
COMPANY PROFILE
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO
Joshua T. Brumm
Full Time Employees
135
CEO Compensation (Base)
$950,000
CEO Compensation (Total)
$6.94M
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO
Joshua T. Brumm
Full Time Employees
135
CEO Compensation (Base)
$950,000
CEO Compensation (Total)
$6.94M
URL
Address
1560 Trapelo Road, MA, Waltham, 02451.
PRICE CHART FOR DYNE THERAPEUTICS INC
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$23.74
Previous Close
$23.65
Days Range
$23.12 - $24.20
52 week range
$6.40 - $30.27
Volume
973,256
Avg. Volume (30 days)
1,002,633
Market Cap
$2.06B
Dividend Yield
-
P/E
-
Shares Outstanding
86,177,719
Open
$23.74
Previous Close
$23.65
Days Range
$23.12 - $24.20
52 week range
$6.40 - $30.27
Volume
973,256
Avg. Volume (30 days)
1,002,633
Market Cap
$2.06B
Dividend Yield
-
P/E
-
Shares Outstanding
86,177,719
FINANCIAL STATEMENTS FOR DYNE THERAPEUTICS INC
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR DYNE THERAPEUTICS INC
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| HIGH SUSANNA GATTI | Chief Operating Officer | Mar 11, 2024 | Sale | $25.70 | 2,292 | 58,904 | 156,800 | Mar 13, 2024, 06:04 AM |
| HIGH SUSANNA GATTI | Chief Operating Officer | Mar 08, 2024 | Sale | $26.67 | 27,199 | 725,344 | 159,383 | Mar 13, 2024, 06:04 AM |
| McNeill Jonathan | Chief Business Officer | Mar 11, 2024 | Option Exercise | $5.54 | 17,825 | 98,750 | 159,009 | Mar 13, 2024, 06:04 AM |
| McNeill Jonathan | Chief Business Officer | Mar 08, 2024 | Option Exercise | $5.54 | 90,000 | 498,600 | 231,184 | Mar 13, 2024, 06:04 AM |
| McNeill Jonathan | Chief Business Officer | Mar 11, 2024 | Sale | $25.50 | 19,601 | 499,842 | 141,184 | Mar 13, 2024, 06:04 AM |
| McNeill Jonathan | Chief Business Officer | Mar 08, 2024 | Sale | $26.24 | 90,000 | 2,361,531 | 196,521 | Mar 13, 2024, 06:04 AM |
| Farwell Wildon | Chief Medical Officer | Mar 12, 2024 | Sale | $25.58 | 1,030 | 26,347 | 150,560 | Mar 12, 2024, 09:58 PM |
| Farwell Wildon | Chief Medical Officer | Mar 11, 2024 | Sale | $25.70 | 1,585 | 40,735 | 151,590 | Mar 12, 2024, 09:58 PM |
| Scalzo Richard William | SVP, Head of Finance & Admin. | Mar 08, 2024 | Option Exercise | $5.54 | 86,252 | 477,836 | 208,207 | Mar 12, 2024, 09:57 PM |
| Scalzo Richard William | SVP, Head of Finance & Admin. | Mar 11, 2024 | Sale | $25.28 | 2,672 | 67,542 | 120,873 | Mar 12, 2024, 09:57 PM |
| Scalzo Richard William | SVP, Head of Finance & Admin. | Mar 08, 2024 | Sale | $26.22 | 86,252 | 2,261,465 | 177,452 | Mar 12, 2024, 09:57 PM |
| Brumm Joshua T | CEO & President | Mar 08, 2024 | Option Exercise | $5.54 | 363,343 | 2,012,920 | 917,728 | Mar 12, 2024, 09:56 PM |
| Brumm Joshua T | CEO & President | Mar 11, 2024 | Option Exercise | $5.54 | 50,000 | 277,000 | 604,385 | Mar 12, 2024, 09:56 PM |
| Brumm Joshua T | CEO & President | Mar 08, 2024 | Sale | $25.93 | 363,343 | 9,421,634 | 715,490 | Mar 12, 2024, 09:56 PM |
| Brumm Joshua T | CEO & President | Mar 11, 2024 | Sale | $25.67 | 66,387 | 1,704,142 | 564,313 | Mar 12, 2024, 09:56 PM |
| Beskrovnaya Oxana | Chief Scientific Officer | Mar 11, 2024 | Sale | $25.70 | 2,081 | 53,482 | 152,352 | Mar 12, 2024, 09:42 PM |
| Brumm Joshua T | CEO & President | Mar 07, 2024 | Sale | $25.85 | 9,086 | 234,873 | 554,385 | Mar 11, 2024, 09:57 PM |
| Beskrovnaya Oxana | Chief Scientific Officer | Mar 07, 2024 | Sale | $25.85 | 2,373 | 61,342 | 154,433 | Mar 11, 2024, 09:56 PM |
| HIGH SUSANNA GATTI | Chief Operating Officer | Mar 07, 2024 | Sale | $25.85 | 1,591 | 41,127 | 186,291 | Mar 11, 2024, 09:56 PM |
| Farwell Wildon | Chief Medical Officer | Mar 07, 2024 | Sale | $25.86 | 9,921 | 256,585 | 154,732 | Mar 11, 2024, 09:52 PM |
| McNeill Jonathan | Chief Business Officer | Mar 07, 2024 | Sale | $25.85 | 2,434 | 62,919 | 141,184 | Mar 11, 2024, 09:50 PM |
| Scalzo Richard William | SVP, Head of Finance & Admin. | Mar 07, 2024 | Sale | $25.85 | 2,273 | 58,757 | 121,955 | Mar 11, 2024, 09:45 PM |
| Rhodes Jason P | Director | Mar 01, 2024 | Sale | $30.05 | 46,534 | 1,398,347 | 1,458,691 | Mar 05, 2024, 05:08 PM |
| Atlas Venture Opportunity Fund I, L.P. | 10% Owner | Mar 01, 2024 | Sale | $30.05 | 17,099 | 513,825 | 847,388 | Mar 05, 2024, 05:07 PM |
| Atlas Venture Opportunity Fund I, L.P. | 10% Owner | Mar 01, 2024 | Sale | $30.05 | 29,435 | 884,522 | 1,458,691 | Mar 05, 2024, 05:07 PM |
| Brumm Joshua T | CEO & President | Mar 01, 2024 | Option Exercise | $5.54 | 94,480 | 523,419 | 657,951 | Mar 01, 2024, 09:38 PM |
| Brumm Joshua T | CEO & President | Feb 29, 2024 | Option Exercise | $5.54 | 5,520 | 30,581 | 568,991 | Mar 01, 2024, 09:38 PM |
| Brumm Joshua T | CEO & President | Mar 01, 2024 | Sale | $29.04 | 94,480 | 2,743,718 | 638,975 | Mar 01, 2024, 09:38 PM |
| Brumm Joshua T | CEO & President | Feb 29, 2024 | Sale | $27.50 | 5,520 | 151,800 | 563,471 | Mar 01, 2024, 09:38 PM |
| McNeill Jonathan | Chief Business Officer | Feb 29, 2024 | Option Exercise | $0.73 | 4,268 | 3,116 | 147,886 | Mar 01, 2024, 09:37 PM |
| McNeill Jonathan | Chief Business Officer | Mar 01, 2024 | Option Exercise | $0.73 | 24,260 | 17,710 | 167,878 | Mar 01, 2024, 09:37 PM |
| McNeill Jonathan | Chief Business Officer | Mar 01, 2024 | Sale | $28.63 | 24,260 | 694,495 | 153,775 | Mar 01, 2024, 09:37 PM |
| McNeill Jonathan | Chief Business Officer | Feb 29, 2024 | Sale | $27.50 | 4,268 | 117,370 | 143,618 | Mar 01, 2024, 09:37 PM |
| Scalzo Richard William | SVP, Head of Finance & Admin. | Mar 01, 2024 | Option Exercise | $1.03 | 9,311 | 9,590 | 133,539 | Mar 01, 2024, 09:37 PM |
| Scalzo Richard William | SVP, Head of Finance & Admin. | Feb 29, 2024 | Option Exercise | $1.03 | 3,429 | 3,532 | 127,657 | Mar 01, 2024, 09:37 PM |
| Scalzo Richard William | SVP, Head of Finance & Admin. | Feb 29, 2024 | Sale | $27.50 | 3,429 | 94,298 | 124,228 | Mar 01, 2024, 09:37 PM |
| Scalzo Richard William | SVP, Head of Finance & Admin. | Mar 01, 2024 | Sale | $28.25 | 9,311 | 262,999 | 124,792 | Mar 01, 2024, 09:37 PM |
| Rhodes Jason P | Director | Feb 28, 2024 | Sale | $24.84 | 190,920 | 4,741,804 | 5,700,521 | Feb 28, 2024, 07:15 PM |
| Rhodes Jason P | Director | Feb 27, 2024 | Sale | $24.41 | 368,699 | 8,998,426 | 5,878,544 | Feb 28, 2024, 07:15 PM |
| Rhodes Jason P | Director | Feb 26, 2024 | Sale | $23.72 | 248,219 | 5,886,673 | 6,216,250 | Feb 28, 2024, 07:15 PM |
| Atlas Venture Fund XI, L.P. | 10% Owner | Feb 26, 2024 | Sale | $23.72 | 47,124 | 1,117,577 | 1,564,932 | Feb 28, 2024, 07:13 PM |
| Atlas Venture Fund XI, L.P. | 10% Owner | Feb 26, 2024 | Sale | $23.72 | 201,095 | 4,769,096 | 6,216,250 | Feb 28, 2024, 07:13 PM |
| Atlas Venture Fund XI, L.P. | 10% Owner | Feb 28, 2024 | Sale | $24.84 | 36,246 | 900,228 | 1,488,486 | Feb 28, 2024, 07:13 PM |
| Atlas Venture Fund XI, L.P. | 10% Owner | Feb 28, 2024 | Sale | $24.84 | 154,674 | 3,841,576 | 5,700,521 | Feb 28, 2024, 07:13 PM |
| Atlas Venture Fund XI, L.P. | 10% Owner | Feb 27, 2024 | Sale | $24.41 | 69,997 | 1,708,338 | 1,514,874 | Feb 28, 2024, 07:13 PM |
| Atlas Venture Fund XI, L.P. | 10% Owner | Feb 27, 2024 | Sale | $24.41 | 298,702 | 7,290,088 | 5,878,544 | Feb 28, 2024, 07:13 PM |
| Farwell Wildon | Chief Medical Officer | Feb 28, 2024 | Sale | $25.00 | 407 | 10,175 | 163,096 | Feb 28, 2024, 05:06 PM |
| Rhodes Jason P | Director | Feb 22, 2024 | Sale | $22.66 | 119,360 | 2,704,698 | 6,512,104 | Feb 23, 2024, 06:59 PM |
| Rhodes Jason P | Director | Feb 21, 2024 | Sale | $22.57 | 184,501 | 4,164,817 | 6,666,628 | Feb 23, 2024, 06:59 PM |
| Rhodes Jason P | Director | Feb 23, 2024 | Sale | $22.70 | 196,928 | 4,470,266 | 6,352,562 | Feb 23, 2024, 06:59 PM |
| Atlas Venture Fund XI, L.P. | 10% Owner | Feb 23, 2024 | Sale | $22.70 | 37,386 | 848,662 | 1,585,137 | Feb 23, 2024, 06:58 PM |
| Atlas Venture Fund XI, L.P. | 10% Owner | Feb 23, 2024 | Sale | $22.70 | 159,542 | 3,621,604 | 6,352,562 | Feb 23, 2024, 06:58 PM |
| Atlas Venture Fund XI, L.P. | 10% Owner | Feb 22, 2024 | Sale | $22.66 | 119,360 | 2,704,698 | 6,512,104 | Feb 23, 2024, 06:58 PM |
| Atlas Venture Fund XI, L.P. | 10% Owner | Feb 21, 2024 | Sale | $22.57 | 184,501 | 4,164,817 | 6,666,628 | Feb 23, 2024, 06:58 PM |
| Rhodes Jason P | Director | Feb 20, 2024 | Sale | $22.72 | 169,539 | 3,852,652 | 6,819,475 | Feb 20, 2024, 06:36 PM |
| Rhodes Jason P | Director | Feb 16, 2024 | Sale | $23.14 | 162,707 | 3,765,040 | 6,985,504 | Feb 20, 2024, 06:36 PM |
| Rhodes Jason P | Director | Feb 15, 2024 | Sale | $23.89 | 177,906 | 4,249,600 | 7,150,324 | Feb 20, 2024, 06:36 PM |
| Atlas Venture Fund XI, L.P. | 10% Owner | Feb 16, 2024 | Sale | $23.14 | 162,707 | 3,765,040 | 6,985,504 | Feb 20, 2024, 06:35 PM |
| Atlas Venture Fund XI, L.P. | 10% Owner | Feb 15, 2024 | Sale | $23.89 | 177,906 | 4,249,600 | 7,150,324 | Feb 20, 2024, 06:35 PM |
| Atlas Venture Fund XI, L.P. | 10% Owner | Feb 20, 2024 | Sale | $22.72 | 169,539 | 3,852,652 | 6,819,475 | Feb 20, 2024, 06:35 PM |
| Farwell Wildon | Chief Medical Officer | Feb 12, 2024 | Sale | $25.07 | 5,493 | 137,710 | 163,503 | Feb 14, 2024, 04:27 PM |
| Farwell Wildon | Chief Medical Officer | Jan 26, 2024 | Sale | $25.00 | 100 | 2,500 | 168,996 | Jan 26, 2024, 07:49 PM |
| McNeill Jonathan | Chief Business Officer | Jan 26, 2024 | Option Exercise | $0.73 | 20,000 | 14,600 | 163,618 | Jan 26, 2024, 07:48 PM |
| McNeill Jonathan | Chief Business Officer | Jan 26, 2024 | Sale | $24.53 | 20,000 | 490,510 | 143,796 | Jan 26, 2024, 07:48 PM |
| Scalzo Richard William | SVP, Head of Finance & Admin. | Jan 26, 2024 | Option Exercise | $1.03 | 13,000 | 13,390 | 137,228 | Jan 26, 2024, 07:47 PM |
| Scalzo Richard William | SVP, Head of Finance & Admin. | Jan 26, 2024 | Sale | $24.34 | 13,000 | 316,420 | 124,228 | Jan 26, 2024, 07:47 PM |
| Kersten Dirk | Director | Jan 09, 2024 | Buy | $17.50 | 1,714,285 | 29,999,988 | 6,416,793 | Jan 11, 2024, 04:31 PM |
| Brumm Joshua T | CEO & President | Jan 04, 2024 | Option Exercise | $5.16 | 218,536 | 1,127,092 | 803,507 | Jan 04, 2024, 09:49 PM |
| Brumm Joshua T | CEO & President | Jan 03, 2024 | Option Exercise | $1.03 | 51,183 | 52,718 | 636,154 | Jan 04, 2024, 09:49 PM |
| Brumm Joshua T | CEO & President | Jan 04, 2024 | Sale | $18.51 | 218,536 | 4,045,958 | 623,272 | Jan 04, 2024, 09:49 PM |
| Brumm Joshua T | CEO & President | Jan 03, 2024 | Sale | $19.28 | 51,183 | 986,957 | 620,772 | Jan 04, 2024, 09:49 PM |
| Beskrovnaya Oxana | Chief Scientific Officer | Jan 04, 2024 | Option Exercise | $1.03 | 22,674 | 23,354 | 199,259 | Jan 04, 2024, 09:48 PM |
| Beskrovnaya Oxana | Chief Scientific Officer | Jan 03, 2024 | Option Exercise | $1.03 | 45,326 | 46,686 | 221,911 | Jan 04, 2024, 09:48 PM |
| Beskrovnaya Oxana | Chief Scientific Officer | Jan 04, 2024 | Sale | $18.13 | 42,453 | 769,673 | 156,806 | Jan 04, 2024, 09:48 PM |
| Beskrovnaya Oxana | Chief Scientific Officer | Jan 03, 2024 | Sale | $18.98 | 45,326 | 860,313 | 206,529 | Jan 04, 2024, 09:48 PM |
| McNeill Jonathan | Chief Business Officer | Jan 03, 2024 | Option Exercise | $0.73 | 17,991 | 13,133 | 161,609 | Jan 04, 2024, 09:47 PM |
| McNeill Jonathan | Chief Business Officer | Jan 04, 2024 | Option Exercise | $0.73 | 2,009 | 1,467 | 145,627 | Jan 04, 2024, 09:47 PM |
| McNeill Jonathan | Chief Business Officer | Jan 02, 2024 | Sale | $13.10 | 11,900 | 155,890 | 143,618 | Jan 04, 2024, 09:47 PM |
| McNeill Jonathan | Chief Business Officer | Jan 04, 2024 | Sale | $18.04 | 2,009 | 36,242 | 143,618 | Jan 04, 2024, 09:47 PM |
| McNeill Jonathan | Chief Business Officer | Jan 03, 2024 | Sale | $18.74 | 17,991 | 337,062 | 153,918 | Jan 04, 2024, 09:47 PM |
| Scalzo Richard William | SVP, Head of Finance & Admin. | Jan 03, 2024 | Option Exercise | $1.03 | 13,000 | 13,390 | 137,228 | Jan 04, 2024, 09:46 PM |
| Scalzo Richard William | SVP, Head of Finance & Admin. | Jan 03, 2024 | Sale | $18.81 | 13,000 | 244,530 | 124,228 | Jan 04, 2024, 09:46 PM |
| Scalzo Richard William | See Remarks | Dec 14, 2023 | Sale | $12.02 | 2,376 | 28,560 | 124,228 | Dec 14, 2023, 04:59 PM |
| Scalzo Richard William | See Remarks | Dec 11, 2023 | Sale | $10.72 | 1,380 | 14,794 | 126,604 | Dec 12, 2023, 05:35 PM |
| McNeill Jonathan | Chief Business Officer | Dec 11, 2023 | Sale | $10.72 | 1,245 | 13,346 | 155,518 | Dec 12, 2023, 05:34 PM |
| HIGH SUSANNA GATTI | Chief Operating Officer | Dec 11, 2023 | Sale | $10.72 | 1,616 | 17,324 | 187,882 | Dec 12, 2023, 05:34 PM |
| Farwell Wildon | Chief Medical Officer | Dec 12, 2023 | Sale | $10.55 | 978 | 10,318 | 169,096 | Dec 12, 2023, 05:33 PM |
| Farwell Wildon | Chief Medical Officer | Dec 11, 2023 | Sale | $10.72 | 1,688 | 18,095 | 170,074 | Dec 12, 2023, 05:33 PM |
| Brumm Joshua T | See Remarks | Dec 11, 2023 | Sale | $10.72 | 7,585 | 81,311 | 584,971 | Dec 12, 2023, 05:33 PM |
| Beskrovnaya Oxana | Chief Scientific Officer | Dec 11, 2023 | Sale | $10.72 | 1,467 | 15,726 | 176,585 | Dec 12, 2023, 05:32 PM |
| Scalzo Richard William | See Remarks | Dec 06, 2023 | Sale | $12.01 | 1,872 | 22,483 | 127,984 | Dec 06, 2023, 06:13 PM |
| Scalzo Richard William | See Remarks | Dec 04, 2023 | Sale | $12.01 | 681 | 8,179 | 129,856 | Dec 06, 2023, 06:13 PM |
| HIGH SUSANNA GATTI | Chief Operating Officer | Nov 02, 2023 | Sale | $7.40 | 9,939 | 73,549 | 94,605 | Nov 02, 2023, 05:16 PM |
| Scalzo Richard William | See Remarks | Sep 18, 2023 | Sale | $9.41 | 1,290 | 12,139 | 40,795 | Sep 20, 2023, 04:49 PM |
| McNeill Jonathan | Chief Business Officer | Sep 18, 2023 | Sale | $9.41 | 1,261 | 11,866 | 60,605 | Sep 20, 2023, 04:49 PM |
| HIGH SUSANNA GATTI | Chief Operating Officer | Sep 18, 2023 | Sale | $9.41 | 2,672 | 25,144 | 104,544 | Sep 20, 2023, 04:48 PM |
| Brumm Joshua T | See Remarks | Sep 18, 2023 | Sale | $9.41 | 12,032 | 113,221 | 233,679 | Sep 20, 2023, 04:47 PM |
| Beskrovnaya Oxana | Chief Scientific Officer | Sep 18, 2023 | Sale | $9.41 | 1,436 | 13,513 | 84,334 | Sep 20, 2023, 04:47 PM |
| Farwell Wildon | Chief Medical Officer | Sep 12, 2023 | Sale | $10.41 | 1,707 | 17,770 | 89,250 | Sep 13, 2023, 07:56 PM |
| Scalzo Richard William | See Remarks | Sep 12, 2023 | Sale | $10.41 | 1,397 | 14,543 | 42,085 | Sep 13, 2023, 07:53 PM |
| McNeill Jonathan | Chief Business Officer | Sep 12, 2023 | Sale | $10.41 | 1,266 | 13,179 | 61,866 | Sep 13, 2023, 07:53 PM |
| HIGH SUSANNA GATTI | Chief Operating Officer | Sep 12, 2023 | Sale | $10.41 | 1,635 | 17,020 | 107,216 | Sep 13, 2023, 07:51 PM |
| Brumm Joshua T | See Remarks | Sep 12, 2023 | Sale | $10.41 | 7,672 | 79,866 | 245,711 | Sep 13, 2023, 07:50 PM |
| Beskrovnaya Oxana | Chief Scientific Officer | Sep 12, 2023 | Sale | $10.41 | 1,484 | 15,448 | 85,770 | Sep 13, 2023, 07:50 PM |
| Scalzo Richard William | See Remarks | Jun 13, 2023 | Option Exercise | $1.03 | 40,000 | 41,200 | 93,482 | Jun 15, 2023, 05:46 PM |
| Scalzo Richard William | See Remarks | Jun 15, 2023 | Sale | $12.03 | 10,000 | 120,300 | 43,482 | Jun 15, 2023, 05:46 PM |
| Scalzo Richard William | See Remarks | Jun 13, 2023 | Sale | $12.87 | 41,390 | 532,878 | 53,482 | Jun 15, 2023, 05:46 PM |
| McNeill Jonathan | See Remarks | Jun 13, 2023 | Sale | $12.43 | 1,259 | 15,649 | 63,132 | Jun 14, 2023, 06:40 PM |
| McNeill Jonathan | See Remarks | Jun 12, 2023 | Sale | $13.00 | 1,000 | 13,000 | 64,391 | Jun 14, 2023, 06:40 PM |
| HIGH SUSANNA GATTI | Chief Operating Officer | Jun 13, 2023 | Sale | $12.43 | 1,625 | 20,199 | 108,851 | Jun 14, 2023, 06:40 PM |
| Farwell Wildon | Chief Medical Officer | Jun 13, 2023 | Sale | $12.43 | 1,698 | 21,106 | 90,957 | Jun 14, 2023, 06:40 PM |
| Beskrovnaya Oxana | Chief Scientific Officer | Jun 13, 2023 | Sale | $12.43 | 1,475 | 18,334 | 87,254 | Jun 14, 2023, 06:39 PM |
| Brumm Joshua T | See Remarks | Jun 08, 2023 | Option Exercise | $1.03 | 30,088 | 30,991 | 330,771 | Jun 12, 2023, 09:22 PM |
| Brumm Joshua T | See Remarks | Jun 12, 2023 | Option Exercise | $1.03 | 171,360 | 176,501 | 441,131 | Jun 12, 2023, 09:22 PM |
| Brumm Joshua T | See Remarks | Jun 09, 2023 | Option Exercise | $1.03 | 76,582 | 78,879 | 346,353 | Jun 12, 2023, 09:22 PM |
| Brumm Joshua T | See Remarks | Jun 12, 2023 | Sale | $12.61 | 187,748 | 2,367,502 | 253,383 | Jun 12, 2023, 09:22 PM |
| Brumm Joshua T | See Remarks | Jun 09, 2023 | Sale | $13.34 | 76,582 | 1,021,604 | 269,771 | Jun 12, 2023, 09:22 PM |
| Brumm Joshua T | See Remarks | Jun 08, 2023 | Sale | $13.22 | 61,000 | 806,690 | 283,960 | Jun 12, 2023, 09:22 PM |
| Scalzo Richard William | See Remarks | Mar 14, 2023 | Sale | $13.33 | 1,311 | 17,476 | 54,872 | Mar 15, 2023, 05:51 PM |
| McNeill Jonathan | See Remarks | Mar 14, 2023 | Sale | $13.33 | 1,209 | 16,116 | 65,391 | Mar 15, 2023, 05:50 PM |
| McNeill Jonathan | See Remarks | Mar 13, 2023 | Sale | $13.00 | 1,000 | 13,000 | 66,600 | Mar 15, 2023, 05:50 PM |
| HIGH SUSANNA GATTI | Chief Operating Officer | Mar 14, 2023 | Sale | $13.33 | 1,559 | 20,781 | 110,476 | Mar 15, 2023, 05:50 PM |
| Farwell Wildon | Chief Medical Officer | Mar 14, 2023 | Sale | $13.33 | 7,441 | 99,189 | 92,655 | Mar 15, 2023, 05:49 PM |
| Brumm Joshua T | See Remarks | Mar 14, 2023 | Sale | $13.33 | 7,318 | 97,549 | 322,483 | Mar 15, 2023, 05:49 PM |
| Beskrovnaya Oxana | Chief Scientific Officer | Mar 14, 2023 | Sale | $13.33 | 1,416 | 18,875 | 88,729 | Mar 15, 2023, 05:48 PM |
| McNeill Jonathan | See Remarks | Jan 18, 2023 | Option Exercise | $0.73 | 10,000 | 7,300 | 77,600 | Jan 23, 2023, 08:27 AM |
| McNeill Jonathan | See Remarks | Jan 18, 2023 | Sale | $14.03 | 10,000 | 140,300 | 67,600 | Jan 23, 2023, 08:27 AM |
| McNeill Jonathan | See Remarks | Jan 09, 2023 | Sale | $11.57 | 30,150 | 348,835 | 67,600 | Jan 11, 2023, 04:56 PM |
| Rhodes Jason P | Director | Dec 12, 2022 | Buy | $10.70 | 934,581 | 10,000,017 | 934,581 | Dec 14, 2022, 04:56 PM |
| Atlas Venture Opportunity Fund II, L.P. | 10% Owner | Dec 12, 2022 | Buy | $10.70 | 934,581 | 10,000,017 | 934,581 | Dec 14, 2022, 04:55 PM |
| Scalzo Richard William | See Remarks | Dec 12, 2022 | Sale | $10.87 | 312 | 3,391 | 56,183 | Dec 13, 2022, 05:06 PM |
| McNeill Jonathan | See Remarks | Dec 12, 2022 | Sale | $10.87 | 472 | 5,131 | 97,750 | Dec 13, 2022, 05:05 PM |
| HIGH SUSANNA GATTI | Chief Operating Officer | Dec 12, 2022 | Sale | $10.87 | 751 | 8,163 | 112,035 | Dec 13, 2022, 05:05 PM |
| Farwell Wildon | Chief Medical Officer | Dec 12, 2022 | Sale | $10.87 | 628 | 6,826 | 100,096 | Dec 13, 2022, 05:04 PM |
| Brumm Joshua T | See Remarks | Dec 12, 2022 | Sale | $10.87 | 3,322 | 36,110 | 329,801 | Dec 13, 2022, 05:04 PM |
| Beskrovnaya Oxana | Chief Scientific Officer | Dec 12, 2022 | Sale | $10.87 | 680 | 7,392 | 90,145 | Dec 13, 2022, 05:03 PM |
| Brumm Joshua T | See Remarks | Oct 10, 2022 | Option Exercise | $1.03 | 195,800 | 201,674 | 400,423 | Oct 11, 2022, 09:00 AM |
| Brumm Joshua T | See Remarks | Oct 07, 2022 | Option Exercise | $1.03 | 14,200 | 14,626 | 218,823 | Oct 11, 2022, 09:00 AM |
| Brumm Joshua T | See Remarks | Oct 10, 2022 | Sale | $12.46 | 195,800 | 2,439,668 | 204,623 | Oct 11, 2022, 09:00 AM |
| Brumm Joshua T | See Remarks | Oct 07, 2022 | Sale | $13.37 | 14,200 | 189,854 | 204,623 | Oct 11, 2022, 09:00 AM |
| Scalzo Richard William | See Remarks | Sep 20, 2022 | Option Exercise | $13.70 | 840 | 11,508 | 25,495 | Sep 21, 2022, 04:09 PM |
| McNeill Jonathan | See Remarks | Sep 20, 2022 | Option Exercise | $13.70 | 1,246 | 17,070 | 58,222 | Sep 21, 2022, 04:08 PM |
| HIGH SUSANNA GATTI | Chief Operating Officer | Sep 20, 2022 | Option Exercise | $13.70 | 2,629 | 36,017 | 68,786 | Sep 21, 2022, 04:08 PM |
| Brumm Joshua T | See Remarks | Sep 20, 2022 | Option Exercise | $13.70 | 11,836 | 162,153 | 204,623 | Sep 21, 2022, 04:07 PM |
| Beskrovnaya Oxana | Chief Scientific Officer | Sep 20, 2022 | Option Exercise | $13.70 | 1,413 | 19,358 | 50,825 | Sep 21, 2022, 04:07 PM |
| Scalzo Richard William | See Remarks | Sep 15, 2022 | Option Exercise | $14.05 | 326 | 4,580 | 26,335 | Sep 15, 2022, 05:30 PM |
| Farwell Wildon | Chief Medical Officer | Sep 15, 2022 | Option Exercise | $14.05 | 658 | 9,245 | 64,724 | Sep 15, 2022, 05:28 PM |
| McNeill Jonathan | See Remarks | Sep 15, 2022 | Option Exercise | $14.05 | 494 | 6,941 | 59,468 | Sep 15, 2022, 05:27 PM |
| HIGH SUSANNA GATTI | Chief Operating Officer | Sep 15, 2022 | Option Exercise | $14.05 | 786 | 11,043 | 71,415 | Sep 15, 2022, 05:26 PM |
| Brumm Joshua T | See Remarks | Sep 15, 2022 | Option Exercise | $14.05 | 3,480 | 48,894 | 216,459 | Sep 15, 2022, 05:25 PM |
| Beskrovnaya Oxana | Chief Scientific Officer | Sep 15, 2022 | Option Exercise | $14.05 | 712 | 10,004 | 52,238 | Sep 15, 2022, 05:24 PM |
| Brumm Joshua T | See Remarks | Jul 06, 2022 | Option Exercise | $8.24 | 10,963 | 90,335 | 219,939 | Jul 06, 2022, 06:18 PM |
| Scalzo Richard William | See Remarks | Jun 14, 2022 | Option Exercise | $4.95 | 333 | 1,648 | 26,661 | Jun 15, 2022, 08:05 PM |
| McNeill Jonathan | See Remarks | Jun 14, 2022 | Option Exercise | $4.95 | 504 | 2,495 | 59,962 | Jun 15, 2022, 08:04 PM |
| HIGH SUSANNA GATTI | Chief Operating Officer | Jun 14, 2022 | Option Exercise | $4.95 | 802 | 3,970 | 72,201 | Jun 15, 2022, 08:03 PM |
| Farwell Wildon | Chief Medical Officer | Jun 14, 2022 | Option Exercise | $4.95 | 668 | 3,307 | 65,382 | Jun 15, 2022, 08:03 PM |
| Brumm Joshua T | See Remarks | Jun 14, 2022 | Option Exercise | $4.95 | 3,540 | 17,523 | 206,784 | Jun 15, 2022, 08:02 PM |
| Beskrovnaya Oxana | Chief Scientific Officer | Jun 14, 2022 | Option Exercise | $4.95 | 726 | 3,594 | 52,950 | Jun 15, 2022, 08:02 PM |
| Scalzo Richard William | See Remarks | Mar 11, 2022 | Sale | $8.73 | 308 | 2,689 | 26,994 | Mar 14, 2022, 05:09 PM |
| McNeill Jonathan | See Remarks | Mar 11, 2022 | Sale | $8.73 | 481 | 4,199 | 60,466 | Mar 14, 2022, 05:09 PM |
| HIGH SUSANNA GATTI | Chief Operating Officer | Mar 11, 2022 | Sale | $8.73 | 765 | 6,678 | 73,003 | Mar 14, 2022, 05:08 PM |
| Farwell Wildon | Chief Medical Officer | Mar 11, 2022 | Sale | $8.73 | 640 | 5,587 | 66,050 | Mar 14, 2022, 05:08 PM |
| Brumm Joshua T | See Remarks | Mar 11, 2022 | Sale | $8.73 | 3,384 | 29,542 | 210,324 | Mar 14, 2022, 05:07 PM |
| Beskrovnaya Oxana | Chief Scientific Officer | Mar 11, 2022 | Sale | $8.73 | 693 | 6,050 | 53,676 | Mar 14, 2022, 05:06 PM |
| Farwell Wildon | Chief Medical Officer | Mar 02, 2022 | Sale | $8.56 | 5,617 | 48,082 | 66,690 | Mar 03, 2022, 07:22 PM |
| HIGH SUSANNA GATTI | Chief Operating Officer | Sep 23, 2021 | Sale | $17.22 | 2,451 | 42,206 | 33,453 | Sep 24, 2021, 10:50 AM |
| Scalzo Richard William | See Remarks | Sep 21, 2021 | Sale | $16.11 | 492 | 7,926 | 10,606 | Sep 22, 2021, 08:03 PM |
| Scalzo Richard William | See Remarks | Sep 20, 2021 | Sale | $15.61 | 367 | 5,729 | 11,098 | Sep 22, 2021, 08:03 PM |
| McNeill Jonathan | See Remarks | Sep 21, 2021 | Sale | $16.11 | 729 | 11,744 | 35,636 | Sep 22, 2021, 08:02 PM |
| McNeill Jonathan | See Remarks | Sep 20, 2021 | Sale | $15.61 | 545 | 8,507 | 36,365 | Sep 22, 2021, 08:02 PM |
| Brumm Joshua T | See Remarks | Sep 21, 2021 | Sale | $16.11 | 4,584 | 73,848 | 99,018 | Sep 22, 2021, 08:02 PM |
| Brumm Joshua T | See Remarks | Sep 20, 2021 | Sale | $15.61 | 3,425 | 53,464 | 103,602 | Sep 22, 2021, 08:02 PM |
| Beskrovnaya Oxana | Chief Scientific Officer | Sep 21, 2021 | Sale | $16.11 | 827 | 13,323 | 17,845 | Sep 22, 2021, 08:01 PM |
| Beskrovnaya Oxana | Chief Scientific Officer | Sep 20, 2021 | Sale | $15.61 | 617 | 9,631 | 18,672 | Sep 22, 2021, 08:01 PM |
| VV Manager II, LLC | 10% Owner | Sep 21, 2020 | Buy | $19.00 | 22,005 | 418,095 | 79,921 | Sep 23, 2020, 07:11 PM |
| VV Manager II, LLC | 10% Owner | Sep 21, 2020 | Buy | $19.00 | 792,995 | 15,066,905 | 2,880,125 | Sep 23, 2020, 07:11 PM |
| Logos Global Management LP | 10% Owner | Sep 21, 2020 | Buy | $19.00 | 700,000 | 13,300,000 | 1,504,392 | Sep 23, 2020, 07:09 PM |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Sep 21, 2020 | Buy | $19.00 | 660,000 | 12,540,000 | 2,805,045 | Sep 23, 2020, 06:55 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| HIGH SUSANNA GATTI | Chief Operating Officer | 03/11/2024 | 58,904 |
| HIGH SUSANNA GATTI | Chief Operating Officer | 03/08/2024 | 725,344 |
| McNeill Jonathan | Chief Business Officer | 03/11/2024 | 98,750 |
| McNeill Jonathan | Chief Business Officer | 03/08/2024 | 498,600 |
| McNeill Jonathan | Chief Business Officer | 03/11/2024 | 499,842 |
| McNeill Jonathan | Chief Business Officer | 03/08/2024 | 2,361,531 |
| Farwell Wildon | Chief Medical Officer | 03/12/2024 | 26,347 |
| Farwell Wildon | Chief Medical Officer | 03/11/2024 | 40,735 |
| Scalzo Richard William | SVP, Head of Finance & Admin. | 03/08/2024 | 477,836 |
| Scalzo Richard William | SVP, Head of Finance & Admin. | 03/11/2024 | 67,542 |
| Scalzo Richard William | SVP, Head of Finance & Admin. | 03/08/2024 | 2,261,465 |
| Brumm Joshua T | CEO & President | 03/08/2024 | 2,012,920 |
| Brumm Joshua T | CEO & President | 03/11/2024 | 277,000 |
| Brumm Joshua T | CEO & President | 03/08/2024 | 9,421,634 |
| Brumm Joshua T | CEO & President | 03/11/2024 | 1,704,142 |
| Beskrovnaya Oxana | Chief Scientific Officer | 03/11/2024 | 53,482 |
| Brumm Joshua T | CEO & President | 03/07/2024 | 234,873 |
| Beskrovnaya Oxana | Chief Scientific Officer | 03/07/2024 | 61,342 |
| HIGH SUSANNA GATTI | Chief Operating Officer | 03/07/2024 | 41,127 |
| Farwell Wildon | Chief Medical Officer | 03/07/2024 | 256,585 |
| McNeill Jonathan | Chief Business Officer | 03/07/2024 | 62,919 |
| Scalzo Richard William | SVP, Head of Finance & Admin. | 03/07/2024 | 58,757 |
| Rhodes Jason P | Director | 03/01/2024 | 1,398,347 |
| Atlas Venture Opportunity Fund I, L.P. | 10% Owner | 03/01/2024 | 513,825 |
| Atlas Venture Opportunity Fund I, L.P. | 10% Owner | 03/01/2024 | 884,522 |
| Brumm Joshua T | CEO & President | 03/01/2024 | 523,419 |
| Brumm Joshua T | CEO & President | 02/29/2024 | 30,581 |
| Brumm Joshua T | CEO & President | 03/01/2024 | 2,743,718 |
| Brumm Joshua T | CEO & President | 02/29/2024 | 151,800 |
| McNeill Jonathan | Chief Business Officer | 02/29/2024 | 3,116 |
| McNeill Jonathan | Chief Business Officer | 03/01/2024 | 17,710 |
| McNeill Jonathan | Chief Business Officer | 03/01/2024 | 694,495 |
| McNeill Jonathan | Chief Business Officer | 02/29/2024 | 117,370 |
| Scalzo Richard William | SVP, Head of Finance & Admin. | 03/01/2024 | 9,590 |
| Scalzo Richard William | SVP, Head of Finance & Admin. | 02/29/2024 | 3,532 |
| Scalzo Richard William | SVP, Head of Finance & Admin. | 02/29/2024 | 94,298 |
| Scalzo Richard William | SVP, Head of Finance & Admin. | 03/01/2024 | 262,999 |
| Rhodes Jason P | Director | 02/28/2024 | 4,741,804 |
| Rhodes Jason P | Director | 02/27/2024 | 8,998,426 |
| Rhodes Jason P | Director | 02/26/2024 | 5,886,673 |
| Atlas Venture Fund XI, L.P. | 10% Owner | 02/26/2024 | 1,117,577 |
| Atlas Venture Fund XI, L.P. | 10% Owner | 02/26/2024 | 4,769,096 |
| Atlas Venture Fund XI, L.P. | 10% Owner | 02/28/2024 | 900,228 |
| Atlas Venture Fund XI, L.P. | 10% Owner | 02/28/2024 | 3,841,576 |
| Atlas Venture Fund XI, L.P. | 10% Owner | 02/27/2024 | 1,708,338 |
| Atlas Venture Fund XI, L.P. | 10% Owner | 02/27/2024 | 7,290,088 |
| Farwell Wildon | Chief Medical Officer | 02/28/2024 | 10,175 |
| Rhodes Jason P | Director | 02/22/2024 | 2,704,698 |
| Rhodes Jason P | Director | 02/21/2024 | 4,164,817 |
| Rhodes Jason P | Director | 02/23/2024 | 4,470,266 |
| Atlas Venture Fund XI, L.P. | 10% Owner | 02/23/2024 | 848,662 |
| Atlas Venture Fund XI, L.P. | 10% Owner | 02/23/2024 | 3,621,604 |
| Atlas Venture Fund XI, L.P. | 10% Owner | 02/22/2024 | 2,704,698 |
| Atlas Venture Fund XI, L.P. | 10% Owner | 02/21/2024 | 4,164,817 |
| Rhodes Jason P | Director | 02/20/2024 | 3,852,652 |
| Rhodes Jason P | Director | 02/16/2024 | 3,765,040 |
| Rhodes Jason P | Director | 02/15/2024 | 4,249,600 |
| Atlas Venture Fund XI, L.P. | 10% Owner | 02/16/2024 | 3,765,040 |
| Atlas Venture Fund XI, L.P. | 10% Owner | 02/15/2024 | 4,249,600 |
| Atlas Venture Fund XI, L.P. | 10% Owner | 02/20/2024 | 3,852,652 |
| Farwell Wildon | Chief Medical Officer | 02/12/2024 | 137,710 |
| Farwell Wildon | Chief Medical Officer | 01/26/2024 | 2,500 |
| McNeill Jonathan | Chief Business Officer | 01/26/2024 | 14,600 |
| McNeill Jonathan | Chief Business Officer | 01/26/2024 | 490,510 |
| Scalzo Richard William | SVP, Head of Finance & Admin. | 01/26/2024 | 13,390 |
| Scalzo Richard William | SVP, Head of Finance & Admin. | 01/26/2024 | 316,420 |
| Kersten Dirk | Director | 01/09/2024 | 29,999,988 |
| Brumm Joshua T | CEO & President | 01/04/2024 | 1,127,092 |
| Brumm Joshua T | CEO & President | 01/03/2024 | 52,718 |
| Brumm Joshua T | CEO & President | 01/04/2024 | 4,045,958 |
| Brumm Joshua T | CEO & President | 01/03/2024 | 986,957 |
| Beskrovnaya Oxana | Chief Scientific Officer | 01/04/2024 | 23,354 |
| Beskrovnaya Oxana | Chief Scientific Officer | 01/03/2024 | 46,686 |
| Beskrovnaya Oxana | Chief Scientific Officer | 01/04/2024 | 769,673 |
| Beskrovnaya Oxana | Chief Scientific Officer | 01/03/2024 | 860,313 |
| McNeill Jonathan | Chief Business Officer | 01/03/2024 | 13,133 |
| McNeill Jonathan | Chief Business Officer | 01/04/2024 | 1,467 |
| McNeill Jonathan | Chief Business Officer | 01/02/2024 | 155,890 |
| McNeill Jonathan | Chief Business Officer | 01/04/2024 | 36,242 |
| McNeill Jonathan | Chief Business Officer | 01/03/2024 | 337,062 |
| Scalzo Richard William | SVP, Head of Finance & Admin. | 01/03/2024 | 13,390 |
| Scalzo Richard William | SVP, Head of Finance & Admin. | 01/03/2024 | 244,530 |
| Scalzo Richard William | See Remarks | 12/14/2023 | 28,560 |
| Scalzo Richard William | See Remarks | 12/11/2023 | 14,794 |
| McNeill Jonathan | Chief Business Officer | 12/11/2023 | 13,346 |
| HIGH SUSANNA GATTI | Chief Operating Officer | 12/11/2023 | 17,324 |
| Farwell Wildon | Chief Medical Officer | 12/12/2023 | 10,318 |
| Farwell Wildon | Chief Medical Officer | 12/11/2023 | 18,095 |
| Brumm Joshua T | See Remarks | 12/11/2023 | 81,311 |
| Beskrovnaya Oxana | Chief Scientific Officer | 12/11/2023 | 15,726 |
| Scalzo Richard William | See Remarks | 12/06/2023 | 22,483 |
| Scalzo Richard William | See Remarks | 12/04/2023 | 8,179 |
| HIGH SUSANNA GATTI | Chief Operating Officer | 11/02/2023 | 73,549 |
| Scalzo Richard William | See Remarks | 09/18/2023 | 12,139 |
| McNeill Jonathan | Chief Business Officer | 09/18/2023 | 11,866 |
| HIGH SUSANNA GATTI | Chief Operating Officer | 09/18/2023 | 25,144 |
| Brumm Joshua T | See Remarks | 09/18/2023 | 113,221 |
| Beskrovnaya Oxana | Chief Scientific Officer | 09/18/2023 | 13,513 |
| Farwell Wildon | Chief Medical Officer | 09/12/2023 | 17,770 |
| Scalzo Richard William | See Remarks | 09/12/2023 | 14,543 |
| McNeill Jonathan | Chief Business Officer | 09/12/2023 | 13,179 |
| HIGH SUSANNA GATTI | Chief Operating Officer | 09/12/2023 | 17,020 |
| Brumm Joshua T | See Remarks | 09/12/2023 | 79,866 |
| Beskrovnaya Oxana | Chief Scientific Officer | 09/12/2023 | 15,448 |
| Scalzo Richard William | See Remarks | 06/13/2023 | 41,200 |
| Scalzo Richard William | See Remarks | 06/15/2023 | 120,300 |
| Scalzo Richard William | See Remarks | 06/13/2023 | 532,878 |
| McNeill Jonathan | See Remarks | 06/13/2023 | 15,649 |
| McNeill Jonathan | See Remarks | 06/12/2023 | 13,000 |
| HIGH SUSANNA GATTI | Chief Operating Officer | 06/13/2023 | 20,199 |
| Farwell Wildon | Chief Medical Officer | 06/13/2023 | 21,106 |
| Beskrovnaya Oxana | Chief Scientific Officer | 06/13/2023 | 18,334 |
| Brumm Joshua T | See Remarks | 06/08/2023 | 30,991 |
| Brumm Joshua T | See Remarks | 06/12/2023 | 176,501 |
| Brumm Joshua T | See Remarks | 06/09/2023 | 78,879 |
| Brumm Joshua T | See Remarks | 06/12/2023 | 2,367,502 |
| Brumm Joshua T | See Remarks | 06/09/2023 | 1,021,604 |
| Brumm Joshua T | See Remarks | 06/08/2023 | 806,690 |
| Scalzo Richard William | See Remarks | 03/14/2023 | 17,476 |
| McNeill Jonathan | See Remarks | 03/14/2023 | 16,116 |
| McNeill Jonathan | See Remarks | 03/13/2023 | 13,000 |
| HIGH SUSANNA GATTI | Chief Operating Officer | 03/14/2023 | 20,781 |
| Farwell Wildon | Chief Medical Officer | 03/14/2023 | 99,189 |
| Brumm Joshua T | See Remarks | 03/14/2023 | 97,549 |
| Beskrovnaya Oxana | Chief Scientific Officer | 03/14/2023 | 18,875 |
| McNeill Jonathan | See Remarks | 01/18/2023 | 7,300 |
| McNeill Jonathan | See Remarks | 01/18/2023 | 140,300 |
| McNeill Jonathan | See Remarks | 01/09/2023 | 348,835 |
| Rhodes Jason P | Director | 12/12/2022 | 10,000,017 |
| Atlas Venture Opportunity Fund II, L.P. | 10% Owner | 12/12/2022 | 10,000,017 |
| Scalzo Richard William | See Remarks | 12/12/2022 | 3,391 |
| McNeill Jonathan | See Remarks | 12/12/2022 | 5,131 |
| HIGH SUSANNA GATTI | Chief Operating Officer | 12/12/2022 | 8,163 |
| Farwell Wildon | Chief Medical Officer | 12/12/2022 | 6,826 |
| Brumm Joshua T | See Remarks | 12/12/2022 | 36,110 |
| Beskrovnaya Oxana | Chief Scientific Officer | 12/12/2022 | 7,392 |
| Brumm Joshua T | See Remarks | 10/10/2022 | 201,674 |
| Brumm Joshua T | See Remarks | 10/07/2022 | 14,626 |
| Brumm Joshua T | See Remarks | 10/10/2022 | 2,439,668 |
| Brumm Joshua T | See Remarks | 10/07/2022 | 189,854 |
| Scalzo Richard William | See Remarks | 09/20/2022 | 11,508 |
| McNeill Jonathan | See Remarks | 09/20/2022 | 17,070 |
| HIGH SUSANNA GATTI | Chief Operating Officer | 09/20/2022 | 36,017 |
| Brumm Joshua T | See Remarks | 09/20/2022 | 162,153 |
| Beskrovnaya Oxana | Chief Scientific Officer | 09/20/2022 | 19,358 |
| Scalzo Richard William | See Remarks | 09/15/2022 | 4,580 |
| Farwell Wildon | Chief Medical Officer | 09/15/2022 | 9,245 |
| McNeill Jonathan | See Remarks | 09/15/2022 | 6,941 |
| HIGH SUSANNA GATTI | Chief Operating Officer | 09/15/2022 | 11,043 |
| Brumm Joshua T | See Remarks | 09/15/2022 | 48,894 |
| Beskrovnaya Oxana | Chief Scientific Officer | 09/15/2022 | 10,004 |
| Brumm Joshua T | See Remarks | 07/06/2022 | 90,335 |
| Scalzo Richard William | See Remarks | 06/14/2022 | 1,648 |
| McNeill Jonathan | See Remarks | 06/14/2022 | 2,495 |
| HIGH SUSANNA GATTI | Chief Operating Officer | 06/14/2022 | 3,970 |
| Farwell Wildon | Chief Medical Officer | 06/14/2022 | 3,307 |
| Brumm Joshua T | See Remarks | 06/14/2022 | 17,523 |
| Beskrovnaya Oxana | Chief Scientific Officer | 06/14/2022 | 3,594 |
| Scalzo Richard William | See Remarks | 03/11/2022 | 2,689 |
| McNeill Jonathan | See Remarks | 03/11/2022 | 4,199 |
| HIGH SUSANNA GATTI | Chief Operating Officer | 03/11/2022 | 6,678 |
| Farwell Wildon | Chief Medical Officer | 03/11/2022 | 5,587 |
| Brumm Joshua T | See Remarks | 03/11/2022 | 29,542 |
| Beskrovnaya Oxana | Chief Scientific Officer | 03/11/2022 | 6,050 |
| Farwell Wildon | Chief Medical Officer | 03/02/2022 | 48,082 |
| HIGH SUSANNA GATTI | Chief Operating Officer | 09/23/2021 | 42,206 |
| Scalzo Richard William | See Remarks | 09/21/2021 | 7,926 |
| Scalzo Richard William | See Remarks | 09/20/2021 | 5,729 |
| McNeill Jonathan | See Remarks | 09/21/2021 | 11,744 |
| McNeill Jonathan | See Remarks | 09/20/2021 | 8,507 |
| Brumm Joshua T | See Remarks | 09/21/2021 | 73,848 |
| Brumm Joshua T | See Remarks | 09/20/2021 | 53,464 |
| Beskrovnaya Oxana | Chief Scientific Officer | 09/21/2021 | 13,323 |
| Beskrovnaya Oxana | Chief Scientific Officer | 09/20/2021 | 9,631 |
| VV Manager II, LLC | 10% Owner | 09/21/2020 | 418,095 |
| VV Manager II, LLC | 10% Owner | 09/21/2020 | 15,066,905 |
| Logos Global Management LP | 10% Owner | 09/21/2020 | 13,300,000 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner | 09/21/2020 | 12,540,000 |
Load More Insider Transactions
FUNDS WITH A POSITION IN DYNE THERAPEUTICS INC
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| BLACKROCK INC. | 3,788,682 | 0.00128% | 14.57% | Other |
| VIVO CAPITAL, LLC | 1,035,136 | 1.13% | No change | Other |
| GEODE CAPITAL MANAGEMENT, LLC | 932,838 | 0.0013% | 8.76% | Other |
| CANDRIAM S.C.A. | 763,624 | 0.07% | 5.53% | Other |
| UBS OCONNOR LLC | 57,330 | 0.05% | -48.24% | Value |
CHANGE IN SHARES OUTSTANDING FOR DYNE THERAPEUTICS INC
STOCK BUYBACKS FOR DYNE THERAPEUTICS INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 12/31/2023
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
09/30/2023
0.49%
1Q
06/30/2023
2.64%
2Q
03/31/2023
9.03%
3Q
12/31/2022
16.25%
4Q
09/30/2022
18.57%
5Q
06/30/2022
18.83%
6Q
03/31/2022
19.01%
7Q
12/31/2021
19.13%
8Q
09/30/2021
19.66%
9Q
06/30/2021
19.91%
10Q
03/31/2021
24.13%
11Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR DYNE THERAPEUTICS INC
LOADING...